Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component

Journal of Clinical Oncology

Volumn 35, Issue 12, 2017, Pages 1288-1296

  Yang, James Chih Hsin ^a   Ahn, Myung Ju ^c   Kim, Dong Wan ^d   Ramalingam, Suresh S ^g   Sequist, Lecia V ^h   Su, Wu Chou ^b   Kim, Sang We ^e   Kim, Joo Hang ^f   Planchard, David ^j   Felip, Enriqueta ^k   Blackhall, Fiona ^l   Haggstrom, Daniel ⁿ   Yoh, Kiyotaka ^o   Novello, Silvia ^q   Gold, Kathryn ^r   Hirashima, Tomonori ^p   Lin, Chia Chi ^a   Mann, Helen ^m   Cantarini, Mireille ^m   Ghiorghiu, Serban ^m   Jänne, Pasi A ⁱ   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c Sungkyunkwan University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Asan Medical Center   (South Korea)

^f CHA University   (South Korea)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m ASTRAZENECA   (United Kingdom)

ⁿ LEVINE CANCER INSTITUTE   (United States)

^o NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^p OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^q UNIVERSITY OF TURIN   (Italy)

^r UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CETUXIMAB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OSIMERTINIB; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; DECREASED APPETITE; DIARRHEA; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PATIENT-REPORTED OUTCOME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; QUALITY OF LIFE; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TABLET FORMULATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 85017605009     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.3223     Document Type: Article

References (29)

1. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: NSCLC (version 4), 2016. http://www.nccn.org/professionals/ physician-gls/pdf/nscl.pdf
2. Reck M, Popat S, Reinmuth N, et al: Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii27-iii39, 2014 (suppl 3)
3. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
4. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010
5. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
6. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327-3334, 2013
7. Wu Y-L, Zhou C, Hu C-P, et al: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol 15:213-222, 2014
8. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patientswith advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
9. Arcila ME, Oxnard GR, Nafa K, et al: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17:1169-1180, 2011
10. Oxnard GR, Arcila ME, Sima CS, et al: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17: 1616-1622, 2011
11. Sun JM, Ahn MJ, Choi YL, et al: Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 82:294-298, 2013
12. Yu HA, Arcila ME, Rekhtman N, et al: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19: 2240-2247, 2013
13. Cross DA, Ashton SE, Ghiorghiu S, et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046-1061, 2014
14. Jänne PA, Yang JC, Kim DW, et al: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689-1699, 2015
15. Goss G, Tsai CM, Shepherd FA, et al: Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17:1643-1652, 2016
16. Brown PD, Jaeckle K, Ballman KV, et al: Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 316:401-409, 2016
17. Soria JC, Wu YL, Nakagawa K, et al: Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. Lancet Oncol 16:990-998, 2015
18. Hu S, Mohan Kumar D, Sax C, et al: Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses. Virology 488:162-168, 2016
19. Janjigian YY, Smit EF, Groen HJ, et al: Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with andwithout T790M mutations. Cancer Discov 4: 1036-1045, 2014
20. Lee CK, Wu YL, Ding PN, et al: Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis. J Clin Oncol 33:1958-1965, 2015
21. Jackman DM, Yeap BY, Sequist LV, et al: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12:3908-3914, 2006
22. Douillard JY, Ostoros G, Cobo M, et al: Firstline gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study. Br J Cancer 110:55-62, 2014
23. Planchard D, Brown KH, Kim DW, et al: Osimertinib western and Asian clinical pharmacokinetics in patients and healthy volunteers: Implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol 77: 767-776, 2016
24. Oxnard GR, Thress KS, Alden RS, et al: Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34: 3375-3382, 2016
25. AstraZeneca: US FDA approves TAGRISSO® (osimertinib) blood-based T790M companion diagnostic test, September 29, 2016. https://www. astrazeneca-us.com/media/press-releases/2016/usfda- approves-tagrisso-osimertinib-blood-based-t790mcompanion- diagnostic-test-09292016.html
26. Ramalingam S, Yang JCH, Lee CK, et al: LBA1-PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: Updated efficacy and safety results from two phase I expansion cohorts. J Thorac Oncol 11:S152, 2016 (suppl 4)
27. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551, 2006
28. Shaw AT, Gandhi L, Gadgeel S, et al: Alectinib in ALK-positive, crizotinib-resistant, nonsmall- cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016
29. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med 354:2531-2541, 2006